PMH45 COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND-ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74764-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)74764-1/fulltext
Title :
PMH45 COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND-ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74764-1&doi=10.1016/S1098-3015(10)74764-1
First page :
Section Title :
Open access? :
No
Section Order :
689